Objective: To detect the expression levels of FAM19A5 in patients with mantle cell lymphoma (MCL), and to determine the relationship between FAM19A5 and the prognosis of MCL patients.
Methods: Twenty-five MCL patients were choosen in the study, cytometric bead assay was used to detected the concentration of FAM19A5 in serum and immunohistochemical analysis were used to detect the expression levels of FAM19A5 in lymph nodes. The relationship of the FAM19A5 expression in serum and tissue were analyzed, the relationship of FAM19A5 and clinical characteristics of MCL patients, treatment and prognosis of MCL patients was analyzed.
Results: The average serum concentration of FAM19A5 in MCL patients was 90.55±38.24 (ng/ml), which was significantly higher than that in control (P=0.0461). The proportion of high, medium, and low expression of FAM19A5 in lymph nodes was 32%, 36% and 32%, respectively, which showed significant difference from that in control group (P=0.001). The expression of FAM19A5 in serum and lymph nodes showed significant correlation (r=0.8683，P=0.001). The serum concentration of FAM19A5 showed positive correlation with the proportion of Ki67 (P=0.0222, r=0.4554). The mean survival time without relapse/death of MCL patients with high, middle and low expression of FAM19A5 was 17, 27 and 37.5 months, respectively，which showed significant statistical difference (P=0.0360). ROC curve analysis showed that serum concentration of FAM19A5 could predict the therapeutic effect in MCL patients, the cut-off value was 91.49 ng/ml. The proportion of recurrent/death in AML patients with FAM19A5 ＞91.49 ng/ml was significantly higher than that in patients with FAM19A5＜91.49 ng/ml (P=0.0156).
Conclusion: The expression level of FAM19A5 is increased in MCL patient, and patients with high expression of FAM19A5 are more likely to relapse or die. FAM19A5 may be a new prognostic marker and potential therapeutic target for MCL.
题目: FAM19A5在套细胞淋巴瘤患者中的表达及其临床意义.
目的: 检测FAM19A5在套细胞淋巴瘤患者中的表达情况，明确其与套细胞淋巴瘤患者预后的关系.
方法: 选择新发套细胞淋巴瘤患者25例，利用流式微球技术检测血清中FAM19A5的浓度，利用免疫组织化学检测淋巴结组织中FAM19A5的表达水平，分析FAM19A5在血清和组织中表达的相关性，分析FAM19A5表达与套细胞淋巴瘤患者临床病理特征的相关性及与治疗和预后的关系.
结果: FAM19A5在套细胞淋巴瘤患者血清中的平 均浓度为90.55±38.24（ng/ml），明显高于正常对照（P=0.0461）。25例患者淋巴结组织中FAM19A5高、中、低表达水平的比例分别为32%、36%和32%，较正常对照组相比具有显著统计学差异（P=0.001）。FAM19A5在血清和淋巴结组织中的表达具有显著的相关性（r=0.8683，P=0.001）。FAM19A5血清浓度与Ki67比例呈明显的正相关（P=0.0222，r=0.4554）。FAM19A5高、中、低表达水平组的平均无复发/死亡存活时间分别为17、27和37.5个月，具有显著的统计学差异（P=0.0360）。应用ROC曲线分析FAM19A5不同血清浓度对套细胞淋巴瘤患者治疗效果的预测作用结果显示，其界值为91.49 ng/ml，13例患者FAM19A5血清浓度＜91.49 ng/ml，其中复发/死亡者2例；12例患者FAM19A5血清浓度＞91.49 ng/ml，其中复发/死亡者8例，两组比较具有显著的统计学差异（P=0.0156）.
结论: FAM19A5在套细胞淋巴瘤中表达水平升高，而且FAM19A5高表达的患者更容易出现复发或死亡，FAM19A5有望成为套细胞淋巴瘤新的预后标志物及潜在的治疗靶点.